Drugs / Pembrolizumab
Pembrolizumab
Drug FDA approvedMarketed as Keytruda
PD-1 (programmed death receptor-1) blocking antibody·First approved·2014·1 brand
- Registered trials
- 2001
- Ongoing
- 917/ 46%
- Completed
- 590
- Indications
- 12
Approved indications by brand
| Brand | Indication |
|---|---|
| Keytruda | Melanoma |
| Non-small cell lung cancer | |
| Head and neck squamous cell cancer | |
| Hodgkin lymphoma | |
| Urothelial cancer | |
| Gastric cancer | |
| Esophageal cancer | |
| Cervical cancer | |
| Hepatocellular carcinoma | |
| Renal cell carcinoma | |
| Endometrial carcinoma | |
| Biliary tract cancer |
Clinical trial landscape
2001 registered studies reference this molecule or one of its brands. The split below shows how many are ongoing versus completed per phase.
| Phase | Total | Ongoing | Completed | Split |
|---|---|---|---|---|
| Phase 2 | 908 | 413 | 251 | |
| Phase 1 | 418 | 168 | 150 | |
| Phase 1/2 | 303 | 131 | 79 | |
| Phase 3 | 257 | 153 | 75 | |
| Early Phase 1 | 33 | 12 | 12 | |
| Unknown | 31 | 5 | 13 | |
| Phase 2/3 | 28 | 20 | 4 | |
| Not applicable | 14 | 9 | 4 | |
| Phase 4 | 9 | 6 | 2 | |
| All phases | 2001 | 917 | 590 |
Ongoing Completed Balance withdrawn, terminated, or status unreported.
Study records: ClinicalTrials.gov →
Mechanism of action
Blocks programmed death receptor-1 (PD-1) signaling as an immune checkpoint inhibitor.
Recent developments
Headlines link to the original publisher. Sources limited to a reviewed list of journals, regulators, and medical press.